Table 1. Urethral stricture management and outcomes following radiation treatment for prostate cancer.
| Study | No. of patients | Median follow-up (months) | Radiation type (%) | Intervention | Mean time to recurrence (months) | Average stricture length cm | Success definition | Success rate | New onset ED | New onset urinary incontinence |
|---|---|---|---|---|---|---|---|---|---|---|
| Meeks 2011 (71) | 30 | 21 | ERBT 50% | EPA 84% | 5.1 | 2.9 | Cystoscopic patency >16 F | 73% | 0% | 5% |
| BT 24% | BMG 6% | |||||||||
| ERBT + BT 26% | Flap 10% | |||||||||
| Glass 2012 (70) | 29 | 40 | ERBT 38% | EPA 76% | 12 | 2.6 | No need for urethral intervention | 90% | N/A | 7% |
| RP + ERBT 24% | BMG | |||||||||
| ERBT + BT 24% | 17% | |||||||||
| BT 14% | Flap 7% | |||||||||
| Hofer 2014 (72) | 66 | 37 | ERBT 42.4% | EPA 100% | 10.2 | 2.3 | Cystoscopic patency >16 F | 69.7% | 0% | 18.5% |
| BT 42.4% | ||||||||||
| ERBT + BT 13.6% | ||||||||||
| Palmer 2015 (73) | 20 | 40 | Radiation 40% | BMG + gracilis flap 100% | 10 | 8.2 | Cystoscopic patency>16 F | 80% | N/A | 25% |
| Prostatectomy 10% | ||||||||||
| Ahyai 2015 (74) | 38 | 26.5 | ERBT 64.9% | BMG 100% | 17 | 3 | No need for urethral intervention | 71.1% | 0% | 10% |
| BT 21.6% | ||||||||||
| ERBT + BT 13.5% | ||||||||||
| Fuchs 2017 (75) | 72 | 50 | ERBT 45.8% | EPA 100% | 33.5 | 2-3 | Cystoscopic patency>16 F | 70-86% | N/A | 35% |
| BT 36.1% | ||||||||||
| ERBT + BT 12.5% | ||||||||||
| Rourke 2016 (76) | 35 | 50.5 | ERBT 57.2% | EPA 65.7% | 29.8 | 3.5 | Cystoscopic patency | 85.7% | 30.4% | 25.7% |
| BT 42.8% | BMG 20% | |||||||||
| Flap 14.3% |